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medication upon discontinuing clopidogrel. CONCLUSION:
Clopidogrel was the dominant oral antiplatelet by market share.
These patients also used signiﬁcant pharmacy resources on other
medications. While average duration was largely consistent with
treatment guidelines, variations in individual treatment length
were detected. This ﬁnding suggests inconsistencies in utilization
versus treatment guidelines. Early discontinuation of cardiac
medications in some patients also raises concern.
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OBJECTIVES: Computed tomography angiography (CTA) scan-
ners have advanced patient care by providing cardiologists with
the latest in imaging technology. When deciding to purchase a
CTA scanner, practices must evaluate the economic feasibility of
ownership in terms of both ﬁxed (eg, equipment and facility
costs) and variable costs (ie, consumables costs). The objective
of this study was to provide cardiology practices with a com-
prehensive cost estimate for the cost of consumables incurred for
CTA procedure. METHODS: Practice patterns from a large car-
diology practice were evaluated for all CTA procedures over an
eight-month timeframe. The various consumables utilized for
CTA procedures were captured and classiﬁed into three main cat-
egories: contrast media, drugs, and medical supplies. The average
utilization of each consumable was then evaluated, and the unit
acquisition cost for each consumable was applied to quantify the
average cost of consumables per CTA procedure. RESULTS:
From January 2006 through August 2006, data from 3119 pro-
cedures were evaluated. The average cost of consumables per
procedure incurred by the practice was $83.31. Of this cost,
$32.55 was incurred for contrast medium. Additionally, $9.91
was the average cost per procedure incurred for drugs such as
beta blockers, solu-medrol, diphenhydramine, intravenous
ﬂuids, nitrolingual spray, and antiemetics. The largest compo-
nent of consumables was medical supplies (eg, syringes, needles,
tubing, cannulae, intravenous catheter, dressing/bandages, table
paper, gloves, alcohol pads, etc), which cost the institution an
average of $40.85 per procedure. CONCLUSION: When evalu-
ating the economic feasibility of operating a CTA scanner, car-
diology practices can expect to incur an average of $83.31 per
procedure for consumables.
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OBJECTIVES: Compare impact of nesiritide (a recombinant
natriuretic peptide approved for intravenous treatment of
ADHF) administration within ﬁrst day versus after ﬁrst day on
in-hospital outcomes using an inpatient claims database of 400+
US hospitals and 600,000+ discharges (PREMIER). METHODS:
From 681,690 discharges during 2003 and 2004 in the
PREMIER database, we studied patients with DRG 127 at dis-
charge and ICD 9 codes for primary diagnosis of CHF. First day
nesiritide (D1) was deﬁned as nesiritide + diuretic administration
within 1st day of hospital admission; post-ﬁrst-day administra-
tion (post-D1) was deﬁned as nesiritide administration after ﬁrst
hospital day with diuretic therapy during ﬁrst day. Four out-
comes variables were analyzed: discharge status, hospital and
ICU LOS, and hospitalization cost. Propensity matching and
propensity covariate adjustments were performed in all regres-
sion analyses to remove bias in between-group comparisons.
RESULTS: In all, 8126 patient discharge episodes were identi-
ﬁed as D1 and 793 as post-D1. The D1 group had reduced mor-
tality odds versus post-D1 (0.46, 95% CI: 0.36, 0.59, P <
0.0001). Hospital and ICU LOS were shorter for D1 versus post-
D1 (−4.5 days [95% CI: −4.9, −4.2, P < 0.0001] and −1.7 days
[95% CI: −2, −1.5, P < 0.0001], respectively). Hospital costs
were lower for D1 patients (D1-Post D1): −$6642 (95% CI: 
−$7226, −$6058, P < 0.0001). Adjusted and unadjusted analy-
ses on all four outcomes were consistent and achieved statistical
signiﬁcance. CONCLUSION: This analysis demonstrated that in
two groups of propensity-matched hospitalized patients, those
treated with nesiritide within the ﬁrst day of hospital admission
have better outcomes than those treated with nesiritide later.
These ﬁndings are based on retrospective data sources. A recently
announced prospective randomized, controlled global clinical
trial enrolling 7000+ patients (ASCEND-HF) will provide addi-
tional information.
CARDIOVASCULAR STUDIES—Health Care Use &
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OBJECTIVES: To study the effects of two sequential changes in
drug cost-sharing policies on adherence to statins and beta-
blockers by seniors in British Columbia. METHODS: For each
drug class, we identiﬁed a baseline cohort of subjects initiating
therapy in the 6 months prior to January 1, 2001, a co-payment
cohort initiating therapy in the 6 months prior to the co-payment
policy introduced January 1, 2002, and a co-insurance cohort
initiating therapy in the 6 months prior the co-insurance policy
introduced May 1, 2003. We calculated the proportion of
patients adherent in each cohort each month, with follow-up for
each cohort beginning at the start of that cohort’s recruitment
period and ending 15 months later. Patients were deﬁned as
adherent during a month if they had a proportion of days
covered (PDC) of 80% or greater, calculated by dividing the
number of days the patient had drug supply available by the
number of cohort membership days the patient contributed in
that calendar month. RESULTS: In the baseline cohort, which
did not experience cost-sharing, 55.8% of statin initiators were
adherent to their statins at month 15. The adherence level in the
co-payment cohort at this time, 9 months after the introduction
of the co-payment policy, was 50.5%. 50.8% of co-insurance
cohort member were adherent. Adherence to beta-blockers was
lower, with 48% of the baseline cohort initiators adherent at
month 15. However, the introduction of the co-payment and co-
insurance policies reduced this adherence level by only 1 per-
centage point. CONCLUSION: The introduction of the
co-payment and co-insurance policies reduced adherence to
statins by 5 percentage points relative to baseline levels, but had
a much smaller effect on beta blocker adherence levels. Policy-
